Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

157
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
157
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

208
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
208
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

187
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
187
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Examining bidirectional longitudinal relationships between physical activity and physical function in older breast cancer survivors: The Thinking and Living with Cancer study.

Cancer·2026
Same author

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

Bone marrow transplantation·2026
Same author

Characterizing Relationships Between Daily Pain, Opioid Use, and Mood in Patients With Advanced Cancer Using Ecological Momentary Assessments.

JCO oncology practice·2026
Same author

A pilot randomized clinical trial of a peer support intervention for hematopoietic stem cell transplantation.

Blood advances·2026
Same author

Association of Sleep Disturbance With Survival After Colorectal Cancer Diagnosis: Results From the ColoCare Study.

Cancer medicine·2026
Same author

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity.

Blood advances·2026

Related Experiment Video

Updated: Jun 19, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.2K

Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Narrative Review and Proposed Theoretical Model.

Kimberley T Lee1, Hailey W Bulls2, Aasha I Hoogland3

  • 1Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Cancers
|July 27, 2024
PubMed
Summary

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect for cancer survivors. A new 3P model identifies predisposing, precipitating, and perpetuating factors to guide future interventions for managing CIPN symptoms.

Keywords:
cancer survivorshipchemotherapy-induced peripheral neuropathytheoretical model

More Related Videos

Chronic Constriction of the Sciatic Nerve and Pain Hypersensitivity Testing in Rats
08:23

Chronic Constriction of the Sciatic Nerve and Pain Hypersensitivity Testing in Rats

Published on: March 13, 2012

58.9K
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

48.1K

Related Experiment Videos

Last Updated: Jun 19, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.2K
Chronic Constriction of the Sciatic Nerve and Pain Hypersensitivity Testing in Rats
08:23

Chronic Constriction of the Sciatic Nerve and Pain Hypersensitivity Testing in Rats

Published on: March 13, 2012

58.9K
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

48.1K

Area of Science:

  • Oncology
  • Neurology
  • Cancer Survivorship

Background:

  • Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and disabling condition affecting cancer survivors.
  • Current interventions for managing CIPN symptoms are limited, highlighting an unmet clinical need.

Purpose of the Study:

  • To propose a framework of predisposing, precipitating, and perpetuating factors (3Ps) for CIPN.
  • To establish a foundation for future research and clinical strategies to mitigate CIPN symptoms and associated morbidity.

Main Methods:

  • A comprehensive literature search was conducted using PubMed.
  • Keywords focused on "chemotherapy-induced peripheral neuropathy."
  • Included studies were limited to those available in full English text.

Main Results:

  • Predisposing factors (e.g., age, comorbidities) identify at-risk patients.
  • Chemotherapy delivery is the primary precipitating factor, potentially manageable with cryotherapy or compression.
  • Perpetuating factors suggest psychological, cognitive, and behavioral targets for management.

Conclusions:

  • The proposed 3P model offers a structured approach to understanding CIPN.
  • Identifies modifiable psychological and behavioral targets for intervention development.
  • Aims to reduce the impact of CIPN on cancer patients' quality of life.